ARA-290 vs BPC-157: Research Comparison
A Side-By-Side Research Comparison Of ARA-290 And BPC-157 - two peptides studied for tissue protection and repair. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| ARA-290 | BPC-157 | |
|---|---|---|
| Category | Immunity & Wellness | Healing & Recovery |
| Compound Class | Non-hematopoietic EPO-derived 11-amino acid cyclic peptide; innate repair receptor agonist | Synthetic pentadecapeptide derived from human gastric juice protein BPC |
| Evidence Tier | Investigational | Research Compound |
| Molecular Target | Innate repair receptor (IRR = EPO-R + CD131 beta-common heterodimer); tissue-protective signaling without erythropoiesis; anti-apoptotic and anti-inflammatory | NO-synthase, VEGF, FAK/paxillin, EGF receptor, growth hormone receptor; promotes angiogenesis, collagen synthesis, and cytoprotection |
| Molecular Weight | 1257.4 Da | 1419.5 Da |
| Amino Acid Sequence | QEQLERALNSS | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| CAS Number | 1208243-50-8 | 137525-51-0 |
| Half-Life | ~2 minutes | ~30 minutes |
| Studied For | Small-fiber neuropathy (sarcoidosis, diabetes), Neuropathic pain research, Tissue-injury repair, Diabetic neuropathy models | GI mucosal healing, Tendon / ligament repair, Nerve repair, Anti-inflammatory |
About ARA-290
An EPO-derived peptide studied for nerve repair and neuropathic pain without the blood-thickening risk of EPO.
Read The Full ARA-290 MonographAbout BPC-157
A popular research healing peptide with strong rodent data but very limited human evidence.
Read The Full BPC-157 MonographKey Differences
- ARA-290 is categorized under Immunity & Wellness, while BPC-157 falls under Healing & Recovery.
- Evidence tier differs: ARA-290 is classified as Investigational; BPC-157 is classified as Research Compound.
- Reported half-life differs: ARA-290 at ~2 minutes versus BPC-157 at ~30 minutes.
- Primary molecular target differs: ARA-290 acts on Innate repair receptor (IRR = EPO-R + CD131 beta-common heterodimer); tissue-protective signaling without erythropoiesis; anti-apoptotic and anti-inflammatory; BPC-157 acts on NO-synthase, VEGF, FAK/paxillin, EGF receptor, growth hormone receptor; promotes angiogenesis, collagen synthesis, and cytoprotection.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.